Johanna Bendell, MD, Sarah Cannon Cancer Institute

Articles by Johanna Bendell, MD, Sarah Cannon Cancer Institute

Applying Data to the Real World in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Emerging Approaches in HER2+ Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

VEGFR TKIs in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Maintenance Therapy in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Adjuvant Treatment in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Looking Toward the Future in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Toxicity Management in Second Line for Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Clinical Rationale for Antiangiogenics in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Predicting Response With Biomarkers in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Applying New Data in the Real-World for GEJ Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

ESMO 2020: Practice-Changing Data in Esophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

First-Line I/O Successful in Gastric Adenocarcinoma

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Frontline Treatment in Metastatic Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Optimal Approach Toward Advanced Gastric Cancers in US

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Global Trends in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Latest Updated Articles

ESMO 2020: Practice-Changing Data in Esophageal Cancer
October 22nd 2020
First-Line I/O Successful in Gastric Adenocarcinoma
October 22nd 2020
Predicting Response With Biomarkers in Gastric Cancers
October 22nd 2020
Optimal Approach Toward Advanced Gastric Cancers in US
October 22nd 2020
Treatment Landscape in Gastric Cancers Pre-ESMO 2020
October 22nd 2020
Applying New Data in the Real-World for GEJ Cancer
October 22nd 2020

Johanna Bendell, MD, Sarah Cannon Cancer Institute

Articles by Johanna Bendell, MD, Sarah Cannon Cancer Institute

Applying Data to the Real World in Gastric Cancer

Emerging Approaches in HER2+ Gastric Cancers

VEGFR TKIs in Gastroesophageal Cancer

Maintenance Therapy in Gastric Cancers

Adjuvant Treatment in Gastroesophageal Cancer

Looking Toward the Future in Gastroesophageal Cancer

Toxicity Management in Second Line for Gastric Cancer

Clinical Rationale for Antiangiogenics in Gastric Cancer

Predicting Response With Biomarkers in Gastric Cancers

Applying New Data in the Real-World for GEJ Cancer

ESMO 2020: Practice-Changing Data in Esophageal Cancer

First-Line I/O Successful in Gastric Adenocarcinoma

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

Frontline Treatment in Metastatic Gastric Cancer

Optimal Approach Toward Advanced Gastric Cancers in US

Global Trends in Gastric Cancers

Latest Updated Articles

Trending on OncLive

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer

Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer

European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer